ARTICLE | Product Development
GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute
Plus SAB gets additional funding from U.S. government, starts human trials
August 13, 2020 1:48 AM UTC
GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma.
GigaGen Inc. plans to submit an IND for its COVID-19 treatment, GIGA-2050, by year-end...